Fig_3.tif (4.77 MB)

Hr-anxA1 attenuates progression into advanced plaques.

figure

posted on 2015-06-19, 04:32 authored by Dennis H. M. Kusters, Martijn L. Chatrou, Brecht A. G. Willems, Marijke De Saint-Hubert, Matthias Bauwens, Emiel van der Vorst, Stefania Bena, Erik A. L. Biessen, Mauro Perretti, Leon J. Schurgers, Chris P. M. Reutelingsperger

(A) 12 weeks old mice were fed WTD 12 weeks. During the last 6 weeks mice were treated with hr-anxA1 or vehicle (ctrl). (A) Representative H&E staining of aortic arches. (B) Treatment with hr-anxA1 significantly reduced total plaque burden in the inner arch (arch) and subclavian artery (SA) but not in the brachiocephalic (BCA) and left common carotid artery (CA). (C) Individual plaque progression was scored on following parameters: neutrophil and macrophage content, apoptosis and necrosis, cap thickness and calcification status (see S1 and S2 Tables). (D, E) Endothelial ICAM-1 expression was reduced in early plaque development (IX/SL) after anxA1 treatment. (F, G) Macrophage and (H, I) smooth muscle cell content were comparable between anxA1 and vehicle treated controls. IX: intimal xanthoma; SL: small lesion; IL: intermediate lesion; AL: advanced lesion. All values are represented as mean ±SEM, n = 12 animals per group. Panel A: 40x magnification, scale bar represents 500μm; Panel D,F: 100x magnification, scale bar represents 200 μm; Panel H: 200x magnification, scale bar represents 100 μm.